The Latest Breaking News from BristolMyers Squibb Company

Consumer confidence dropped month-over-month in November. However, it remains well above the mark, indicating a healthy economy. We think investors’ quality stocks, UnitedHealth Group (UNH) and Bristol-Myers Squibb (BMY), which have solid dividend-paying records, could help navigate the uncertainties. However, fundamentally weak Peloton Interactive (PTON) and Mullen Automotive (MULN) might…

The Fed is likely to slow down its aggressive monetary policy as analysts believe the economy is finally losing momentum and inflation should decline in the next year. Therefore, investors should consider adding fundamentally sound stocks Bristol-Myers (BMY) and ARC Document (ARC) to their portfolios to ensure a stable passive…

As the Fed approved its fourth supersized rate hike early this month, consumer sentiment is slightly worse for the month and the near future. Moreover, the IMF issued a gloomier outlook for the global economy. Therefore, fundamentally solid stocks Bristol-Myers Squibb (BMY), Cigna Corporation (CI), and J.Jill (JILL) could be…

Global biopharmaceutical company Bristol-Myers Squibb (BMY) reported solid third-quarter financials and is well-positioned to witness immense growth in the upcoming quarters, driven by continued progress in its diverse product pipeline. Moreover, the stock is trading above its 50-day and 200-day moving averages, indicating an uptrend. Thus, we think it could…

Although the stock market has been under pressure this year due to macroeconomic headwinds, the pharmaceutical industry continues to garner investor attention as it enjoys inelastic demand for its products regardless of economic conditions. Thus, fundamentally-sound pharma stocks Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) could be worth your attention…

With the Fed set to launch another supersized rate hike later this week to tame the stubborn inflation, the risk of a recession is only growing. Therefore, we think investors should consider buying fundamentally strong stocks Bristol-Myers Squibb Company (BMY) and TravelCenters of America (TA), which are A-rated in our…

Leading biopharmaceutical company Bristol-Myers Squibb (BMY) reported solid financials in the last quarter. Its diversified product portfolio and inelastic demand for such products brighten its near-term prospects. Moreover, the company’s strong financials put it in a great position to pay dividends increasingly. Hence, it could be an ideal pick for…

Medical sector tends to be relatively recession-proof due to the inelastic demand for its products and services. And given the solid prospects of the industry, investors could consider buying fundamentally sound medical stocks Johnson & Johnson (JNJ) and Bristol-Myers (BMY), which look poised for a bull run in Q4. Read…

The central bank might deliver another big rate hike next month to tame the persistently high inflation. However, the corporate earnings season has been gearing up investors’ sentiments. We believe fundamentally sound stocks Bristol-Myers Squibb (BMY), Energy Transfer (ET), and Kroger (KR), which have consistently reported strong financials this year,…